<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Pfizer-BioNTech</th>
<th>Moderna</th>
<th>Janssen</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vaccine type</strong></td>
<td>mRNA</td>
<td>mRNA</td>
<td>Replication-incompetent adenovirus type 26 vector</td>
</tr>
<tr>
<td><strong>Age groups</strong></td>
<td>5 through 11 years of age</td>
<td>12 years of age and older</td>
<td>≥18 years</td>
</tr>
<tr>
<td><strong>Dose</strong></td>
<td>10 µg (orange cap)</td>
<td>30 µg (purple cap)</td>
<td>100 µg (primary series and additional primary dose)</td>
</tr>
<tr>
<td><strong>Dosage (volume)</strong></td>
<td>0.2 mL</td>
<td>0.3 mL</td>
<td>50 µg (booster dose)</td>
</tr>
<tr>
<td><strong>Number of doses in primary series</strong></td>
<td>2</td>
<td>2</td>
<td>5x10¹⁰ viral particles</td>
</tr>
<tr>
<td><strong>Interval between primary series doses</strong></td>
<td>3 weeks (21 days)</td>
<td>1 month (28 days)</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Additional primary dose for moderately or severely immunocompromised persons</strong></td>
<td>Currently not authorized or recommended for this age group</td>
<td>Recommended at least 28 days after the 2nd dose of the primary series for moderately and severely immunocompromised people 12 years of age and older [<a href="https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#considerations-covid-19-vax-immunocompromised">https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#considerations-covid-19-vax-immunocompromised</a>] Use the same vaccine product as the primary series See information below about a booster dose.</td>
<td>Not authorized as an additional primary dose. See information below about a booster dose.</td>
</tr>
<tr>
<td><strong>Booster dose</strong></td>
<td>Currently not recommended for this age group</td>
<td>A booster dose at least 6 months after the completed primary series (or additional primary dose for moderately or severely immunocompromised) should be given for:</td>
<td>A single booster dose should be administered to all people 18 years and older who received a primary single-dose Janssen COVID-19 Vaccine*</td>
</tr>
<tr>
<td><strong>Interval between primary and booster doses</strong></td>
<td>n/a</td>
<td>At least 6 calendar months after completing the primary series or additional primary dose (for moderately or severely immunocompromised)</td>
<td>At least 2 months (8 weeks) after receiving the primary dose</td>
</tr>
</tbody>
</table>
The Pfizer-BioNTech formulation for children aged 5-11 years (orange cap) is not interchangeable with the Pfizer-BioNTech formulation for people aged ≥12 years (purple cap).

Any FDA-approved or –authorized COVID-19 vaccine can be used for the booster dose. When a different product is used, the eligible population and dosing intervals are those of the vaccine used for the primary series. (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#Interchangeability).

COVID-19 vaccines can be given to people with prior SARS-CoV-2 infection. Defer vaccination until person has recovered from the acute illness and criteria have been met for them to discontinue isolation (https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-in-home-patients.html).

COVID-19 vaccines can be given; however, a conversation between the patient, guardian, and clinical team to discuss benefits and risks of receiving a COVID-19 vaccine is encouraged.

COVID-19 vaccine not recommended for community outbreaks or post-exposure prophylaxis. People in community or outpatient setting should defer vaccination until quarantine period has ended (https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/quarantine.html).

Residents or patients in congregate settings may be vaccinated if they do not have symptoms consistent with COVID-19 (https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html).

Can receive any FDA-authorized or approved vaccine but should be informed of risk of TTS after receipt of Janssen (Johnson & Johnson) COVID-19 Vaccine and the availability of other COVID-19 vaccine options.

If within 90 days of illness, offer an mRNA vaccine, vaccinate with any FDA-authorized or approved COVID-19 vaccine, including Janssen COVID-19 Vaccine.

May receive COVID-19 vaccine.

If received doses of COVID-19 vaccine prior to receiving an HCT or CAR-T cell therapy, should be revaccinated with a primary series at least 3 months (12 weeks) after transplant or CAR-T-cell therapy.

If myocarditis or pericarditis occurred after a dose of an mRNA COVID-19 vaccine:
- Until additional safety data are available, some experts recommend the Janssen COVID-19 Vaccine be given to persons aged ≥ 18 years who want to receive a subsequent dose.
- This decision should include a conversation between the patient and their clinical team.
- If a history of myocarditis or pericarditis unrelated to an mRNA COVID vaccination, may receive COVID-19 vaccine after the episode has completely resolved.
- A subsequent dose can be considered in certain circumstances including personal risk of severe COVID-19 and level of community transmission.
## All currently authorized or approved COVID-19 vaccines

<table>
<thead>
<tr>
<th>Persons with a history of Guillain-Barré Syndrome (GBS)</th>
<th>- Can receive any FDA-authorized or approved COVID-19 vaccine; however, discuss the availability of mRNA vaccines because of possible association between GBS and Janssen COVID-19 vaccination.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnant or breastfeeding people or people trying to get pregnant</td>
<td>- Are recommended to receive a COVID-19 vaccine primary series, &quot;additional primary dose (if indicated) and booster dose&quot;, inform of risk of TTS after receipt of Janssen COVID-19 Vaccine and the availability of other options</td>
</tr>
</tbody>
</table>
| Children and adolescents | - Children and adolescents aged 5-17 are ONLY eligible for Pfizer-BioNTech COVID-19 Vaccine  
- Children aged 5-11 years - 10 ug (0.2mL dosage) Pfizer-BioNTech (orange cap)  
- Adolescents aged ≥ 12 years - 30ug (0.3 mL dosage) Pfizer-BioNTech (purple cap)  
- Adolescents and adults aged 18 years and older are eligible for all COVID-19 vaccine product  
- Additional primary doses are not recommended at this time for children <12 years of age who are moderately or severely immunocompromised.  
  - Because of the risk of syncope, especially in adolescents, recipients should be observed for 15 minutes after vaccination |
| Persons vaccinated outside the United States | - Received all recommended doses of an FDA-authorized or approved COVID-19 vaccine, do not need primary series doses; if only one dose of a two-dose vaccine has been received provide the second dose as close to the recommended time as possible.  
- Received a non-FDA-authorized or -approved vaccine  
  - If vaccine is listed for emergency use by the World Health Organization (WHO) and received all recommended doses, do not need any additional primary series doses with an FDA-authorized or approved vaccine  
  - If vaccine is listed for emergency use by WHO, but has not received all recommended doses, may be offered a complete FDA-authorized or -approved series  
  - If vaccine is not listed for emergency use by WHO, may be offered a complete FDA-authorized or approved COVID-19 vaccine series  
  - If received a mixed dose regimen of FDA-approved, FDA-authorized, or WHO-emergency use listed COVID-19 vaccine for primary series, do not need any primary series doses.  
| Contraindications | - Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to component of the COVID-19 vaccine  
- Contradiction to one type of COVID-19 vaccines (mRNA) is a precaution to other types of COVID-19 vaccines (Janssen) |
| Precaution | - Immediate (within 4 hours exposure) non-severe allergic reaction to a previous dose or known (diagnosed) allergy to a component of the vaccine  
- Immediate allergic reaction to any other vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies [excluding subcutaneous immunotherapy for allergies, i.e., "allergy shots"])) |
| Post-vaccination observation periods | - 30 minutes: people with a history of:  
  - A contraindication to another type of COVID-19 vaccine product (i.e., mRNA or viral vector COVID-19 vaccines)  
  - Immediate (within 4 hours of exposure) non-severe allergic reaction to a COVID-19 vaccine  
  - Immediate allergic reaction of any severity to a non-COVID-19 vaccine or injectable therapies  
  - Anaphylaxis due to any cause  
- 15 minutes: all other persons |
| SARS-CoV-2 antibody testing | - Antibody testing not recommended for vaccine decision-making or to assess immunity following vaccination |

*Any person who develops TTS after a Janssen primary dose should NOT get a Janssen booster.  
† Although CDC provides considerations for a mixed series in exceptional circumstances for a primary or additional primary dose ([https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html#Interchangeability](https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html#Interchangeability)), this is still considered an administration error that requires VAERS reporting. Heterologous booster doses are allowed and are not considered a vaccine error.